Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREATH: Benralizumab Effect on Airway Remodeling in Severe Eosinophilic Asthmatics
NCT06288516Phase 4Completed
- Sponsor
- Aristotle University of Thessaloniki
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of benralizumab in eosinophilic asthma (EA), sponsored by Aristotle University of Thessaloniki. Started Mar 2024; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT06288516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06288516.